EUCTR2007-006115-23-FRActive, not recruitingPhase 1
Effects of nebivolol on the cardiovascular functions, thermoregulation and blood flow during real and simulated conditions of microgravity - MISSION Medicine In Space Study - Investigation Of Nebivolol
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Berlin-Chemie AG
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Written informed consent
- •2. Male or female
- •3. Age 20 - 45 years
- •4. The subject is healthy as judged by the responsible physician, with no clinically significant abnormality identified during the screening evaluation or medical history, including ECG
- •5. Non-smoker
- •6. The subject is willing and able to participate in both study parts (tilting-table part and parabolic flight part)
- •7. Positive standard medical check-up for parabolic flight
- •8. The subject has a normal cardiovascular adjustment during tilting-table tests
- •9. The subject is willing to restrain a normal fluid supply before the tilting-table tests without a subjective feeling of thirst
- •10. The subject is able and willing to understand and comply with the requirements, restrictions and instructions defined in the trial protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. The subject has a concomitant illness and/or nebivolol and/or scopolamine specific contraindications apply:
- •- Liver insufficiency or liver function impairment
- •- Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy
- •- Sick sinus syndrome, including sino-atrial block
- •- Second and third degree heart block
- •- History of bronchospasm and bronchial asthma
- •- Untreated phaeochromocytoma
- •- Metabolic acidosis
- •- Bradycardia (heart rate < 60 bpm prior to start of treatment)
- •- Hypotension (systolic blood pressure < 90 mmHg)
- •- Severe peripheral circulatory disturbances
- •- Narrow-angle glaucoma
- •- Prostatic hypertrophy in male subjects
- •- Pyloric obstruction
- •2. Known idiosyncrasy (hypersensitivity) to nebivolol and/or scopolamine or to any of the ingredients of the study drugs, or any known hypersensitivity to beta-blocker and/or anti-cholinergic drugs
- •3. Known motion sickness
- •4. Known fear of flying and/or abnormal nervousness
- •5. The subject is participating or has participated within the previous three months in a clinical study with an investigational or a non-investigational drug or device
- •6. The subject has participated in more than three studies within the past year
- •7. The subject is using any prescription or non-prescription drugs, vitamins, herbal and dietary supplements (including St John's Wort) within seven days or five half lives (which-ever is the longer) prior to the first dose of study medication
- •8. Clinically relevant symptoms within seven days prior to start of study
- •9. Any condition (surgical or medical) which will affect absorp-tion, distribution, metabolism and/or excretion of the study drug
- •10. Need for continuous medical treatment within seven days or five half lives (whichever is longer) prior to or during the study with the exception of contraceptives and scopolamine for prevention of motion sickness
- •11. History or presence of alcohol or substance abuse
- •12. Alcohol intake 24 hours prior to or during study visits
- •13. Regular consumption of large amounts of caffeine-containing beverages (equivalent to more than six cups of coffee per day)
- •14. Pregnancy or lactation
- •15. Female subjects not willing to use appropriate contraceptive measures for the duration of the study and for at least one month after the last dose of study drug. Medically accept-able contraceptives include e.g.: (1) surgical sterilization, (2) approved hormonal contraceptives, (3) 3-months injection, (4) combined oral methods (combination of methods with a gel, spray, foam, salve or suppository), (5) some kind of loop. Sexual abstinence or vasectomy of the partner are also acceptable measures to avoid pregnancy
- •16. The subject has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
Investigators
Similar Trials
Recruiting
Not Applicable
Effects of nebivolol on the cardiorespiratory parametershealthy.Healthy person accompanying sick personZ76.3IRCT20220603055064N1Muhmmad institute of medical and allied sciences200
Recruiting
Phase 4
Effect of oral tablet nebivolol on improving the inner lining of blood vesselsCTRI/2012/01/002384JIPMER80
Terminated
Phase 4
An Advanced Echocardiographic Evaluation of NebivololHypertensionNCT01206439Jack Rubinstein2
Completed
Phase 4
Effects of Nebivolol Versus Metoprolol Succinate on Endothelial FunctionHypertensionNCT01248338Berlin-Chemie AG Menarini Group80
Completed
Phase 3
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African AmericansHypertensionNCT00145210Mylan Bertek Pharmaceuticals630